Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) EPS (Basic): 2014-2025

Historic EPS (Basic) for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to -$0.91.

  • KalVista Pharmaceuticals' EPS (Basic) rose 14.95% to -$0.91 in Q2 2025 from the same period last year, while for Apr 2025 it was -$3.69, marking a year-over-year decrease of 31.79%. This contributed to the annual value of -$3.69 for FY2025, which is 7.27% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported EPS (Basic) of -$0.91 as of Q2 2025, which was down 4.60% from -$0.87 recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' EPS (Basic) registered a high of -$0.84 during Q1 2024, and its lowest value of -$1.07 during Q2 2024.
  • Moreover, its 2-year median value for EPS (Basic) was -$0.89 (2025), whereas its average is -$0.92.
  • Data for KalVista Pharmaceuticals' EPS (Basic) shows a peak YoY rose of 14.95% (in 2025) over the last 5 years.
  • KalVista Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$0.87 in 2024, then climbed by 14.95% to -$0.91 in 2025.
  • Its EPS (Basic) stands at -$0.91 for Q2 2025, versus -$0.87 for Q3 2024 and -$1.07 for Q2 2024.